- Home
- LPAA vs VNDA Comparison
LPAA vs VNDA Comparison
Compare LPAA & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPAA
- VNDA
- Stock Information
- Founded
- LPAA 2024
- VNDA 2002
- Country
- LPAA United States
- VNDA United States
- Employees
- LPAA N/A
- VNDA N/A
- Industry
- LPAA
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- LPAA
- VNDA Health Care
- Exchange
- LPAA Nasdaq
- VNDA Nasdaq
- Market Cap
- LPAA 289.2M
- VNDA 270.0M
- IPO Year
- LPAA 2024
- VNDA 2006
- Fundamental
- Price
- LPAA $10.07
- VNDA $4.51
- Analyst Decision
- LPAA
- VNDA Strong Buy
- Analyst Count
- LPAA 0
- VNDA 2
- Target Price
- LPAA N/A
- VNDA $15.50
- AVG Volume (30 Days)
- LPAA 44.1K
- VNDA 499.8K
- Earning Date
- LPAA 01-01-0001
- VNDA 02-05-2025
- Dividend Yield
- LPAA N/A
- VNDA N/A
- EPS Growth
- LPAA N/A
- VNDA N/A
- EPS
- LPAA N/A
- VNDA N/A
- Revenue
- LPAA N/A
- VNDA $190,858,000.00
- Revenue This Year
- LPAA N/A
- VNDA $5.60
- Revenue Next Year
- LPAA N/A
- VNDA $42.85
- P/E Ratio
- LPAA N/A
- VNDA N/A
- Revenue Growth
- LPAA N/A
- VNDA N/A
- 52 Week Low
- LPAA $9.66
- VNDA $3.46
- 52 Week High
- LPAA $10.07
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- LPAA N/A
- VNDA 42.95
- Support Level
- LPAA N/A
- VNDA $4.77
- Resistance Level
- LPAA N/A
- VNDA $4.95
- Average True Range (ATR)
- LPAA 0.00
- VNDA 0.15
- MACD
- LPAA 0.00
- VNDA -0.03
- Stochastic Oscillator
- LPAA 0.00
- VNDA 31.82
About LPAA Launch One Acquisition Corp. Class A Ordinary shares
Launch One Acquisition Corp is a blank check company.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.